12 enrolling by invitation. 12 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Enrolling by invitation 12 |
| Phase 2 | 6 | Enrolling by invitation 6 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis Low molecular weight fucoidan and standard care, Placebo and standard of care - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Enrolling by invitation | Allama Iqbal Medical College | 90 | 2026-08-01 | 2026-08-26 |
| A Phase I Clinical Trial of CPU-YL01 Injection in Patients With Chronic Hepatitis B. CPU-YL01 Injection Intramuscular administration, Placebo intramuscular injection - Chronic Hepatitis B | Phase 1 | Enrolling by invitation | Jiangsu Chuangyuan Life Science and Technology Co., Ltd. | 74 | 2026-07-03 | 2026-11-05 |
| To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants LYNC-101, LYNC-101 Placebo - UC - Ulcerative Colitis | Phase 1 | Enrolling by invitation | LyncBio Therapeutics Co., Ltd. | 50 | 2026-05-28 | 2026-08-27 |
| Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined. Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol - Autism Spectrum Disorder, Autism | Phase 1 / Phase 2 | Enrolling by invitation | Black Tie Medical, Inc. | 50 | 2026-04-30 | 2026-04-27 |
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 RNDO-564, Pembrolizumab - Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Enrolling by invitation | Rondo Therapeutics | 149 | 2025-11-17 | 2026-06-11 |
| Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer Leucine-restricted diet. - Gastric Cancer | Phase 1 | Enrolling by invitation | Qilu Hospital of Shandong University | 37 | 2025-10-01 | 2026-04-20 |
| JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study JS014 Combined With Toripalimab and TACE - Hepatocellular Carcinoma (HCC) | Phase 1 | Enrolling by invitation | Xiangya Hospital of Central South University | 20 | 2025-07-10 | 2025-09-19 |
| XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI, Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI - Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation | Phase 1 / Phase 2 | Enrolling by invitation | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 102 | 2025-05-23 | 2026-09-25 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors - Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Man Hu | 100 | 2024-03-30 | 2025-03-30 |
| Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma paclitaxel, carboplatin, tislelizumab - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Qiu Guoqin | 30 | 2022-06-01 | 2024-03-12 |
| Fecal Microbiome Transplant Fecal Microbiota Transplant - Clostridium Difficile, Inflammatory Bowel Disease | Phase 1 | Enrolling by invitation | Judith Kelsen | 250 | 2015-12-01 | 2026-04-15 |
Carcinoma, Non-Small-Cell Lung (3) · Colitis, Ulcerative (3) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colitis (1) · Colorectal Neoplasms (1) · Communication (1) · Crohn Disease (1) · Glioblastoma (1)
Gastrointestinal Diseases (10) · Digestive System Neoplasms (7) · Neoplasms by Site (7) · Gastrointestinal Neoplasms (6) · Neoplasms (6) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Carcinoma (4) · Colonic Diseases (4) · Esophageal Diseases (4) · Head and Neck Neoplasms (4) · Intestinal Diseases (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3)
Fecal Microbiota Transplantation (2) · Anti-Inflammatory Agents (1) · Carboplatin (1) · Folfox protocol (1) · Immunomodulation (1) · Injections (1) · Paclitaxel (1) · Radiotherapy (1) · Standard of Care (1) · pembrolizumab (1) · tislelizumab (1) · toripalimab (1)
Allama Iqbal Medical College (1) · Black Tie Medical, Inc. (1) · Jiangsu Chuangyuan Life Science and Technology Co., Ltd. (1) · Judith Kelsen (1) · LyncBio Therapeutics Co., Ltd. (1) · Man Hu (1) · Qilu Hospital of Shandong University (1) · Qiu Guoqin (1) · Rondo Therapeutics (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Stella Pharma Corporation (1) · Xiangya Hospital of Central South University (1)
China (6) · United States (3) · Australia (1) · Japan (1) · Pakistan (1)
Cexiong Fu (1) · Judith Kelsen, MD (1) · Liangrong Shi, M.D. (1) · Man Hu, Dr. (1) · Rozina Shahadat Khan, MBBS, M.PHIL,MSPH, CHPE,PHDHND (1) · Thomas Manley, MD (1)